Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Targeted therapy for cancer (1)
3. Targeted therapy for cancer (2)
4. Targeted therapy for cancer (3)
5. Involvement of angiogenesis in tumor formation
6. VEGF: molecular characteristics
7. VEGF and angiogenic switch in tumors
8. Tumour vasculature is abnormal
9. VEGF produces immature tortuous vessels
10. VEGF is an attractive target for anticancer therapy
11. RhuMAb VEGF (bevacizumab/Avastin)
12. Significant reduction in microvasculature
13. Anti-VEGF antibody improves drug delivery
14. Avastin: An anti-VEGF agent for cancer therapy
15. Avastin trial evidence
16. IFL + Avastin vs. IFL: increase in RR and duration
17. Superior PFS+ OS with first-line IFL + Avastin
18. AVF2107g: Avastin-related adverse events
19. Analysis of Avastin+ 5-FU-based regimens
20. Use of Avastin with FOLFIRI-based therapy
21. Phase II trial of Avastin plus FOLFIRI (AVIRI)
22. Phase II trial of Avastin + FOLFIRI (AVIRI) - results
23. Use of Avastin with oxaliplatin-based therapy
24. Second-line Avastin + FOLFOX - results
25. Avastin and oxaliplatin-based chemotherapy
26. Ongoing phase III trial of XELOX and Avastin
27. NO16966 met both primary endpoints
28. PFS chemotherapy + bevacizumab superiority
29. BOND-2: randomised phase II trial
30. Conclusions
31. Study schema
32. Study organisation

Topics Covered

• Targeted therapy for cancer
• Angiogenesis is involved throughout tumour formation, growth and metastasis
• VEGF: molecular characteristics
• VEGF and other signals promote the angiogenic switch in tumours
• Tumour vasculature is abnormal
• VEGF produces immature tortuous vessels dependent on VEGF for survival
• Other features make VEGF an attractive target for anticancer therapy
• RhuMAb VEGF (bevacizumab/Avastin(R))
• Significant reduction in microvasculature
• Anti-VEGF antibody improves drug delivery
• Avastin: an anti-VEGF agent for cancer therapy
• Use of Avastin with oxaliplatin-based therapy
• Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response
• Study schema and organization

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Kerr, D. (2009, January 6). Changing paradigms in anticancer drug development: inhibiting angiogenesis in colorectal cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/TWZM9202.
Export Citation (RIS)

Publication History

• Published on January 6, 2009
• Archived on February 25, 2021

Financial Disclosures

• Prof. David Kerr has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.